Carvedilol for preventing recurrent variceal bleeding: Waiting for convincing evidence
Jaime Bosch – 28 January 2013
Faldaprevir combined with pegylated interferon alfa‐2a and ribavirin in treatment‐naïve patients with chronic genotype1 HCV: SILEN‐C1 trial
Mark S. Sulkowski, Tarik Asselah, Jacob Lalezari, Peter Ferenci, Hugo Fainboim, Barbara Leggett, Fernando Bessone, Stefan Mauss, Jeong Heo, Yakov Datsenko, Jerry O. Stern, George Kukolj, Joseph Scherer, Gerhard Nehmiz, Gerhard G. Steinmann, Wulf O. Böcher – 28 January 2013 – Faldaprevir (BI 201335) is a potent, hepatitis C virus (HCV) NS3/4A protease inhibitor with pharmacokinetic properties supportive of once‐daily (QD) dosing.
Hepatitis B testing and access to care among racial and ethnic minorities in selected communities across the United States, 2009‐2010
Dale J. Hu, Jian Xing, Rania A. Tohme, Youlian Liao, Henry Pollack, John W. Ward, Scott D. Holmberg – 28 January 2013 – Hepatitis B virus (HBV) infection is widely prevalent among racial and ethnic minorities in the United States; however, few data have been available regarding HBV testing and referral to care for these populations. Using survey data collected in 2009‐2010 from the Racial and Ethnic Approaches to Community Health (REACH) across the U.S., we assessed rates and determinants of hepatitis B testing and access to care in 28 minority communities in the U.S.
Faldaprevir combined with pegylated interferon alfa‐2a and ribavirin in treatment‐naïve patients with chronic genotype1 HCV: SILEN‐C1 trial
Mark S. Sulkowski, Tarik Asselah, Jacob Lalezari, Peter Ferenci, Hugo Fainboim, Barbara Leggett, Fernando Bessone, Stefan Mauss, Jeong Heo, Yakov Datsenko, Jerry O. Stern, George Kukolj, Joseph Scherer, Gerhard Nehmiz, Gerhard G. Steinmann, Wulf O. Böcher – 28 January 2013 – Faldaprevir (BI 201335) is a potent, hepatitis C virus (HCV) NS3/4A protease inhibitor with pharmacokinetic properties supportive of once‐daily (QD) dosing.
Prognostic significance of von willebrand factor in cirrhosis: A possible mechanism
Chundamannil E. Eapen, Joshua E. Elias, Ian Mackie, Elwyn Elias – 24 January 2013
PROPEL: A randomized trial of mericitabine plus peginterferon alpha‐2a/ribavirin therapy in treatment‐naïve HCV genotype 1/4 patients
Heiner Wedemeyer, Donald Jensen, Robert Herring, Peter Ferenci, Mang‐Ming Ma, Stefan Zeuzem, Maribel Rodriguez‐Torres, Natalie Bzowej, Paul Pockros, John Vierling, David Ipe, Marie Lou Munson, Ya‐Chi Chen, Isabel Najera, James Thommes, on behalf of the PROPEL Investigators – 24 January 2013 – Mericitabine is a nucleoside analog polymerase inhibitor of hepatitis C virus (HCV).
The antimalarial ferroquine is an inhibitor of hepatitis C virus
Thibaut Vausselin, Noémie Calland, Sandrine Belouzard, Véronique Descamps, Florian Douam, François Helle, Catherine François, Dimitri Lavillette, Gilles Duverlie, Ahmed Wahid, Lucie Fénéant, Laurence Cocquerel, Yann Guérardel, Czeslaw Wychowski, Christophe Biot, Jean Dubuisson – 24 January 2013 – Hepatitis C virus (HCV) is a major cause of chronic liver disease. Despite recent success in improving anti‐HCV therapy, additional progress is still needed to develop cheaper and interferon (IFN)‐free treatments.
SIRT2 overexpression in hepatocellular carcinoma mediates epithelial to mesenchymal transition by protein kinase B/glycogen synthase kinase‐3β/β‐catenin signaling
Juan Chen, Anthony W.H. Chan, Ka‐Fai To, Weixian Chen, Zhenzhen Zhang, Jihua Ren, Chunli Song, Yue‐Sun Cheung, Paul B.S. Lai, Suk‐Hang Cheng, Margaret H.L. Ng, Ailong Huang, Ben C.B. Ko – 24 January 2013 – Sirtuin 1 (SIRT1) has been implicated in telomere maintenance and the growth of hepatocellular carcinoma (HCC). Nevertheless, the role of other sirtuins in the pathogenesis of HCC remains elusive. We found that sirtuin 2 (SIRT2), another member of the sirtuin family, also contributes to cell motility and invasiveness of HCC.
Thyroid hormone‐responsive SPOT 14 homolog promotes hepatic lipogenesis, and its expression is regulated by Liver X receptor α through a sterol regulatory element‐binding protein 1c–dependent mechanism in mice
Jing Wu, Chunjiong Wang, Shuo Li, Sha Li, Wanyi Wang, Jing Li, Yujing Chi, Hang Yang, Xiaomu Kong, Yunfeng Zhou, Chengyan Dong, Fan Wang, Guoheng Xu, Jichun Yang, Jan‐Åke Gustafsson, Youfei Guan – 24 January 2013 – The protein, thyroid hormone‐responsive SPOT 14 homolog (Thrsp), has been reported to be a lipogenic gene in cultured hepatocytes, implicating an important role of Thrsp in the pathogenesis of nonalcoholic fatty liver disease (NAFLD).
Clinical effect and safety profile of recombinant human lysosomal acid lipase in patients With cholesteryl ester storage disease
Manisha Balwani, Catherine Breen, Gregory M. Enns, Patrick B. Deegan, Tomas Honzík, Simon Jones, John P. Kane, Vera Malinova, Reena Sharma, Eveline O. Stock, Vassili Valayannopoulos, J. Edmond Wraith, Jennifer Burg, Stephen Eckert, Eugene Schneider, Anthony G. Quinn – 24 January 2013 – Cholesteryl ester storage disease (CESD), an inherited deficiency of lysosomal acid lipase (LAL), is an underappreciated cause of progressive liver disease with no approved therapy. Presenting features include dyslipidemia, elevated transaminases, and hepatomegaly.